Business
Scribe Therapeutics Achieves Second Success Milestone for In Vivo Program in Collaboration with Eli Lilly and Company
ALAMEDA, Calif., February 17, 2026--Scribe Therapeutics achieves second success milestone for in vivo program in collaboration with Eli Lilly and Company
About this update from Eli Lilly And Company
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":2937,"height":807,"url":"https://media.zenfs.com/en/business-wire.com/9e0012b3318dee45c22f366152a08c01"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ZtnfRyHg1fWJ6HafMNbthw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTI2NDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/9e0012b3318dee45c22f366152a08c01","width":960,"height":264},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/yHu.ui3Bbw91gEtdQV.AtQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD02NjA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/9e0012b3318dee45c22f366152a08c01","width":1200,"height":330}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Milestone achieved in Scribe and Lilly’s ongoing collaboration to develop in vivo CRISPR-based therapeutics for neurological and neuromuscular diseases","length":151,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Achievement validates Scribe’s technologies and strengthens momentum across its genetic medicine portfolio, including its internal pipeline advances for cardiovascular and metabolic disease","length":189,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":340,"olType":false},{"type":"text","content":"ALAMEDA, Calif., February 17, 2026--(BUSINESS WIRE)--Scribe Therapeutics, Inc. (Scribe), a biotechnology company pioneering highly engineered CRISPR technologies designed to reshape the treatment of disease by enabling earlier intervention, improved outcomes, and longer, healthier lives, today announced the achievement of a second success milestone for one of the targets in its collaboration with Eli Lilly and Company (NYSE: LLY). The companies are working towards developing in vivo CRISPR-based genetic medicines for neurological and neuromuscular disorders.","length":564,"tagName":"p"},{"type":"text","content":"This latest milestone is a testament to the companies’ ongoing progress in accelerating the development of next-generation therapies by using Scribe’s proprietary X-Editor (XE) technology and is the second such event in Scribe and Lilly’s collaboration. The achievement further validates CRISPR by Design™, Scribe’s holistic, data-driven, and iterative engineering approach to deliberately optimize CRISPR-based medicin...